Kaveh Ehsanipoor, MD
Endocrinology, Diabetes & Metabolism · Savannah, GANPI 1821037706
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $55,700 of the $76,115 with a category attached, or 73.2%. 60 manufacturers reported payments, led by Amgen at 45.8% of the total. Reporting peaked in 2019 at $44,317 and has fallen 98.6% since, to $603 in 2025. Among endocrinology, diabetes & metabolism clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 645 payments — averaging $118.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$35K
- AstraZeneca$32K
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- Mannkind Corporation$572
- Sanofi-aventis U.S. LLC$556
- plus $5K from 54 others
What the payments were for
- Speaking & faculty fees$55,70073%
- Travel & lodging$6,6069%
- Food & beverage$13,71118%
- Education$980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$76,115 in reported general payments places this provider in the 95th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 198 | $273,927 |
| OzempicSemaglutide | 164 | $243,615 |
| FarxigaDapagliflozin Propanediol | 120 | $137,143 |
| TymlosAbaloparatide | 27 | $86,313 |
| Tresiba Flextouch U-100Insulin Degludec | 82 | $56,373 |
| JardianceEmpagliflozin | 33 | $38,768 |
| TrulicityDulaglutide | 21 | $35,009 |
| Tresiba Flextouch U-200Insulin Degludec | 27 | $33,957 |
| Repatha SureclickEvolocumab | 11 | $18,008 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 25 | $17,642 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $13,569 |
| Novolog FlexpenInsulin Aspart | 38 | $9,165 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $4,326 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 37 | $4,255 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $3,800 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $1,488 | $310,147230 claims |
| Novo NordiskOzempic | $1,092 | $243,615164 claims |
| AstraZenecaFarxiga | $32,046 | $137,143120 claims |
| Radius Health, Inc.Tymlos | $465 | $86,31327 claims |
| Boehringer IngelheimJardiance | $256 | $38,76833 claims |
| AbbVieSynthroid | $294 | $3,29739 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $1,25897 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Savannah
- Ismary DecastroSavannah$169K
- Joseph DehavenSavannah$58K
- Carolyn NelsonSavannah$25K
- James StoeverSavannah$11K
- Bruce BodeAtlanta$1.5M
- David RobertsonAtlanta$1.4M
- Adeniyi OdugbesanLawrenceville$636K
- Miguel MunozMarietta$476K
- Jason BernerJasper$457K
- Dawn Smiley-ByrdTaylorsville$385K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.